



1 EOP

1632
4

PATENT
Customer No. 22,852
Attorney Docket No. 9960.0001-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Campbell et al.

Application No.: 09/989,128

Filed: November 21, 2001

For: UNACTIVATED OOCYTES AS CYTOPLAST
RECIPIENTS FOR NUCLEAR TRANSFER

)
)
) Group Art Unit: 1632
)
) Examiner: D. Crouch
)
) Confirmation No. 1813
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION OF TERMINAL DISCLAIMERS

Applicant was contacted by the Examiner on January 26, 2007, who indicated that Terminal Disclaimers were needed to obviate potential obviousness-type double patenting rejections over U.S. Patent No. 6,548,741; U.S. Application No. 09/650,194; U.S. Application No. 09/658,862; U.S. Application No. 10/190,617; and U.S. Application No. 10/914,161.

Solely to expedite allowance of the pending claims, and not in acquiescence to these rejections, Applicant submits herewith two Terminal Disclaimers in the above-referenced application, executed by an attorney of record.

Please associate these papers with the above-identified application. The requisite fee of \$260.00 is enclosed.

Applicant was further informed by the Examiner that a copy of a previously filed Terminal Disclaimer over U.S. Application No. 09/989,125 was missing from the file.

Applicant encloses herewith a copy of this Terminal Disclaimer, previously filed on April 12, 2002. As the fee for filing this Terminal Disclaimer was previously submitted, no fee is currently due for the submission of a copy of this document.

Please grant any extensions of time required to enter these papers and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

Dated: March 9, 2007

By: _____

Salvatore J. Arrigo

Reg. No. 46,063

Telephone: 202-408-4160

Facsimile: 202-408-4400

E-mail: arrigos@finnegan.com



PATENT
Customer No. 22,852
Attorney Docket No. 07681.0018-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
CAMPBELL et al.) Group Art Unit: 1632
)
Serial No.: 09/989,128) Examiner: D. Crouch
)
Filed: November 21, 2001)
)
For: UNACTIVATED OOCYTES AS)
CYTOPLAST RECIPIENTS)
FOR NUCLEAR TRANSFER)

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

TERMINAL DISCLAIMER

Assignees, Roslin Institute and Department for Environment, Food & Rural Affairs (having taken over the governmental functions of the Minister of Agriculture, Fisheries & Food), represent that they are the assignees of the entire right, title and interest in and to the instant application, Application No. 09/989,128, filed November 21, 2001.

Assignees hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application No. 09/989,125, filed November 21, 2001, of any patent on the pending second Application. Assignees hereby agree that any patent

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

~~03/12/2007 07:00:00 00000022-09989128~~

~~01 FC:1814~~

~~130.00-00~~

so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on Application No. 09/989,125 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignees do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent issuing from any patent granted on Application No. 09/989,125, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$110.00 is being filed with this disclaimer. If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to our Deposit Account No. 06-0916.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

The undersigned is an attorney of record.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 12, 2002

By: 
Kenneth J. Meyers
Reg. No. 25,146

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com